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A Genome-Wide Association Study Identifies a
Candidate Gene Associated With Atazanavir
Exposure Measured in Hair
Bani Tamraz1, Yong Huang1, Audrey L. French2, Seble Kassaye3, Kathryn Anastos4, Marek J. Nowicki5,
Stephen Gange6, Deborah R. Gustafson7, Peter Bacchetti8, Ruth M. Greenblatt1,8, Pirro G. Hysi9,10 and
Bradley E. Aouizerat11
Hair provides a direct measure of long-term exposure of atazanavir (ATV). We report the results of the first genome-wide
association study (GWAS) of ATV exposuremeasured in hair in an observational cohort representative of US women living
with HIV; theWomen’s Interagency HIV Study. Approximately 14.1 million single nucleotide polymorphisms (SNPs) were
analyzed in linear regression-based GWAS, with replication, adjusted for nongenetic predictors collected under conditions
of actual use of ATV in 398 participants. Lastly, the PharmGKB database was used to identify pharmacogene associations
with ATV exposure. The rs73208473, within intron 1 of SORCS2, resulted in a 0.46-fold decrease in ATV exposure, with the
strongest association (P51.7131028) in GWAS. A priori pharmacogene screening did not identify additional variants sta-
tistically significantly associated with ATV exposure, including those previously published in ATV plasma candidate pharma-
cogene studies. The findings demonstrate the potential value of pharmacogenomic GWAS in ethnically diverse populations
under conditions of actual use.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Candidate gene studies have identiﬁed pharmacogenetic variants
that inﬂuence the pharmacokinetics of atazanavir (ATV) in plasma.
However, these ﬁndings are derived from study samples poorly
representing conditions and populations actually using ATV.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study evaluated women and treatment-related variables
collected under conditions of actual use of ATV to identify
genetic associations with ATV concentration in hair, a measure
of long-term exposure.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 The association of SORCS2 rs73208473 with reduced ATV
exposure reached genome-wide signiﬁcance. The results suggest
that speciﬁc genetic polymorphisms associated with ATV expo-
sure may differ when assessed in hair among phenotypically and
behaviorally complex HIV-positive women under conditions of
actual use.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 The gap between clinical trials participants and clinical pop-
ulations limits generalizability of clinical trial-based pharmaco-
genetic studies and may bias studies against detection of
signiﬁcant predictors of response. A better understanding of
factors that contribute to medication outcomes is critical for
optimizing treatment for all patients.
Twenty to forty percent of patients using combination antiretroviral
therapy (cART) fail to achieve sustained virological suppression.1–5
With over one million individuals currently living with HIV in the
US,6 this implies 200,000–400,000 Americans are at risk for subopti-
mal HIV treatment outcomes. Therapeutic and toxic effects of most
drugs, including antiretrovirals (ARVs), are directly related to drug
exposure.7,8 In addition to host genetics, drug exposure and response
are inﬂuenced by a variety of nongenetic factors including adherence,
comorbidities, and concomitant medications.9 Most studies that have
measured pharmacokinetics (PK) and pharmacodynamics (PD) of
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ARVs observe this variability, but are unable to account for a large
proportion of the observed variability.
Given the current expectation that cART will be indeﬁnite in
duration,10,11 it is crucial to develop models that can predict out-
comes in the setting of comorbidities and in genetically diverse
populations.
Much of the information we have on the determinants of
ARV exposure is based on studies that enroll participants with
fewer comorbidities and concurrent medications, more limited
ethnic diversity, and fewer women as compared to patients in
clinical care.12 The gap between clinical trial-eligible participants
and clinical populations often limits generalizability and may bias
studies against detection of important factors that inﬂuence ARV
exposure.
Atazanavir (ATV), a potent inhibitor of HIV-1 protease,13 has
been a common component of cART regimens. Despite its favor-
able pharmacologic properties that enable once-a-day dosing, the
PK of ATV is associated with high inter- and intraindividual var-
iabilities in exposure.14 Innate factors that inﬂuence ATV plasma
concentration and PK parameters described in the literature
include variations in ABCB1,15–18 NR1I2,19,20 CYP3A4/A521,22
from candidate gene studies, and nongenetic factors that cur-
rently include adherence,21 race/ethnicity,22 and sex.18 There is a
paucity of published literature evaluating ethnicity, concurrent
medications, other comorbidities, and comprehensive evaluation
of candidate genes associated with ATV exposure. An under-
standing of genetic and nongenetic factors, especially under con-
ditions of actual use of ATV, is important for optimizing and
maintaining ATV concentrations for consistent inhibition of
viral replication. The Women’s Interagency HIV Study (WIHS)
has conducted extensive pharmacologic and genetic characteriza-
tion in representative, understudied, and ethnically diverse
women. The current study utilizes a hypothesis-generating design
that examines genome-wide data (including pharmacogenome) to
ﬁnd genetic variants that inﬂuence ATV exposure; this approach
can identify novel variants and previously unconsidered candidate
pharmacogenes.
RESULTS
Table 1 summarizes the characteristics of women who contrib-
uted data to these analyses. Self-reported adherence for all partici-
pants at the visit with the highest measured concentration of
ATV in hair was 95%. Figure 1a depicts ATV concentrations
Table 1 Demographics and clinical characteristics of study
participants
Characteristic
Hair data groupa
(n5398)
Age (years)c 43.968.7
BMI (kg/m2) 28.567.12
Height (m)c 1.6160.07
Self-reported ethnicity, n (%)
White (Non-Hispanic) 64 (16.1%)
African-American (Non-Hispanic) 194 (48.7%)
Hispanic 130 (32.7%)
Asians, Pacific Islanders
and others
10(2.51%)
CrCl (n5392), n (%)c
Normal (>90 ml/min) 89 (22.7%)
Mild impairment (60-90 ml/min) 216 (55.1%)
Moderate impairment (30-59 ml/min) 79 (20.1%)
Severe impairment (<30 ml/min) 8 (2.0%)
EGFRb (mL/min/1.73 m2)c 91.7626.4
Self-reported adherence, n (%)
>595% 398 (100%)
75-94% 0 (0)
<75% 0 (0)
HBV antigen positive (n5394), n (%) 6 (1.3%)
HCV RNA positive, n (%) 69 (17.3%)
Liver enzymes (IU)
ALT 26.9629.3
AST 29.4620.1
GGTc 45.3664.2
Bilirubin, total (mg/dl) 1.761.2
Crack use (n5394), n (%) 18 (4.5%)
Cocaine use (n5394), n (%)c 3 (0.8%)
Heroin use (n5394), n (%) 5 (1.2%)
Smoker, n (n5394) (%) 160 (40.1%)
Alcohol use (n5394), n (%)
Abstain 259 (65.7%)
>0-7 drinks/week 121(30.7%)
>7-12 drinks/week 9 (2.3%)
>12 drinks/week 5 (1.3%)
Drug interaction variables, n (%)
Medications that decrease ATV exposure 170 (42.7%)
Antacids 21 (5.3%)
Ritonavirc 339 (85.2%)
Table 1 Continued on next column
Table 1 Continued
Characteristic
Hair data groupa
(n5398)
Not pregnant (n5397), n (%) 394 (99.2%)
ALT, alanine aminotransferase; ATZ, atazanavir; AST, aspartate aminotransferase;
BMI, body mass index; CrCl, creatinine clearance; eGFR, estimated glomerular fil-
tration rate; CKD-EPI, chronic kidney disease epidemiology collaboration equation;
GTT, gamma-glutamyl transferase; HBV, Hepatitis B virus; HCV, hepatitis C virus;
IU, international units.
aData are expressed as mean6 standard deviation except if specified otherwise
(i.e., n (%)). beGFR was calculated using the CKD-EPI equation. cGWAS analysis
adjusted for the following nongenetic predictors.
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measured in hair for all participants over all visits. The mean
ATV level was 4.346 4.41 ng/mg of hair. Participants reported
concurrent use of ritonavir with ATV in the majority of visits
(85%). WIHS has previously published on the existence of a rela-
tionship between ATV level in hair and virologic suppression,23
and a similar trend exists in the current sample (Figure 1b).
Although ATV dose was not recorded, we assumed that any par-
ticipant who is on ritonavir is on a dose of 300mg of ATV,
boosted with 100mg ritonavir (a standard dose). The percent of
participants on an ATV/ritonavir regiment in each hair quintile
with undetectable viral load (i.e., <80 copies/mL) is comparable
to values calculated for all participants in this study (Figure 1b).
Of 398 individuals providing ATV measures, 379 participants
passed all quality control (QC) criteria for inclusion in the
genome-wide association study (GWAS): 190 African-Americans
(AA), 57 Caucasians (WT), and 53 Hispanic (HIS). The addi-
tional 79 subjects who were either ethnically admixed or did not
ﬁt in any particular ethnic cluster were retained for replication
analysis. Three strata were sufﬁciently large for GWAS analysis
(i.e., AA, WT, HIS). The genomic control factor inﬂation was
low for each group (1.004, 1.052, and 1.005 respectively),
suggesting that there was no major admixture or stratiﬁcation
effects left uncontrolled in the samples.
Combining the three strata identiﬁed a strong association
between ATV level and a cluster of 16 single nucleotide polymor-
phisms (SNPs) on chromosome 4p16.1 (Figure 2). The most sta-
tistically signiﬁcant SNP in this cluster (rs73208473,
P5 1.7131028, Table 2), is a noncoding SNP located within a
linkage disequilibrium (LD) block that contains intron 1 of the
SORCS2 gene (Table 2, Figures 2, 3). On average, each copy of
the rs73208473 minor “A” allele was associated with a 46%
decrease in ATV levels (95% conﬁdence interval (CI) 0.35–0.61,
Figure 3). Although an imputed SNP, rs73208473 had an excel-
lent imputation score (RSQ5 0.973) and was in high LD with
other directly measured SNPs showing strong association with
ATV levels (r25 0.86 across our entire multiethnic sample with
rs73208470, association with ATV level P5 8.04310208). SNP
rs73208473 is relatively common, with allele frequencies of
0.118, 0.319, and 0.119 in the AA, WT, and HIS participants,
respectively.
Replication in independent samples is standard practice for
GWAS.24 Given the unavailability of additional ATV measurements
Figure 1 Atazanavir (ATV) hair concentrations measured in hair (n51,575) (a) and percent of participants in each hair quintile with undetectable viral
load (i.e., <80 copies/mL) (b).
Figure 2 Manhattan plot of the GWAS results from the meta-analysis of ATV exposure. The genomic position for each SNP for 22 autosomes are plotted
along the x-axis, and the values on the y-axis denote the –log10-transformed and k-adjusted P-values from the meta-analysis of the associations with ATV
hair level for each of the SNPs present in 240 WIHS participants. The green line denotes the a priori threshold for genome-wide significance
(P5531028).
ARTICLES
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 00 NUMBER 00 | MONTH 2018 3
in hair, we ﬁt a linear regression model in the 79 remaining partici-
pants who were not included in the initial stratiﬁed analysis. While
the effect was in the same direction as with those observed in the strati-
ﬁed discovery analysis: Each additional copy of “A” allele was associ-
ated with a 0.87-fold reduction of ATV hair levels (95% CI 0.50–
1.49, Figure 4), this ﬁnding was not statistically signiﬁcant (P5 0.31).
We evaluated SNPs listed in the PharmGKB database to assess
for associations of any of the variants previously cataloged for any
pharmacogenomic effects with ATV exposure in the current
study. Supplemental Table S3 describes the associations of the
136 variants that were below the nominal statistical threshold of
signiﬁcance (P< 0.05). While variants in numerous genes previ-
ously unknown to impact ATV concentration were associated
with a decrease or increase in ATV level in hair (i.e., RRM1,
rs12806698, fold difference5 0.57, 95% CI, 0.42–0.78; ABCC2,
fold difference5 1.4, 95% CI, 1.11–1.78), none exceeded the
Bonferroni threshold (P< 1.29310205) and must be viewed as
preliminary.
We also evaluated variants in the ABCB1,15–18 NR1I2,19,20 and
CYP3A521,22 genes reported in previous ATV pharmacogenetic
literature (Table S4). None of those variants substantially inﬂu-
enced the ATV concentration in hair, but conﬁdence intervals
were too wide to rule out the possibility of an effect (Table S4).
While other variants in these genes (i.e., ABCB1, rs2373586, fold
difference5 1.36, 95% CI, 0.94–1.98; CYP3A4/A5, rs2246709,
fold difference5 1.26, 95% CI, 0.99–1.59; NR1I2, rs3732356,
fold difference5 1.22, 95% CI, 0.93–1.61) were associated with
ATV concentration in hair, the conﬁdence intervals were too wide
to rule out the possibility of no effect. The associations among
these three gene variants and hair ATV levels had large P values
(P> 0.05) in the sample after adjusting for multiple testing.
DISCUSSION
We carried out what is, to our knowledge, the ﬁrst GWAS of
ATV concentration measured in hair. The WIHS cohort is com-
posed of participants who are representative of female HIV
patients in the United States. These participants were assessed
under the condition of actual ATV use and we adjusted for
potential confounders. We built on the diversity of this cohort to
test genome-wide in each ancestral group independently and
then applied meta-analysis methods, demonstrating the value of
GWAS methods applied to diverse populations in identifying
new genetic factors that inﬂuence drug exposure. ARV exposure
in hair is of interest because it is a readily accessible biomatrix
representing longer duration of exposures and arguably longer-
term ATV exposure (6 weeks) as compared with plasma. Fur-
thermore, while hair is not the site of action for HIV medication,
Figure 3 Regional association plots and recombination rates of the locus
associated with ATV hair level. Data of both directly genotyped and
imputed SNPs are presented. The SNP with the most significant associa-
tion is denoted with a purple diamond. The plot was created using Locus-
Zoom.49 The color coding of all other SNPs in linkage disequilibrium (LD)
with rs73208473, estimated by CEU r2 from phase II HapMap is provided,
with an LD of: red, r20.8; yellow, 0.6 r2<0.8; green, 0.4 r2<0.6;
cyan, 0.2 r2<0.4,; blue r2<0.2 ; and gray, r2 unknown. The left y axis
(points) represents –log10 P values for each SNP association, the right y
axis (lines, mostly obscured) represents the recombination rate, estimated
from the International HapMap Project,50 and the x axis represents base-
pair positions along the chromosome 4 based on human genome build 37.
Table 2 Results from GWAS, meta-analysis, and replication for association with ATV hair level in WIHS
rsID Genotyped or imputed Chr. Positiona A1/A2 allele MAF Ethnic group (n) Fold difference (95% CI) P
rs73208473 Imputed 4 7324596 A/C 0.118 AA (194) 0.54 (0.37-0.80) 0.0025
0.319 WT (57) 0.34 (0.24-0.51) 3.0931026
0.119 HIS (53) 0.91 (0.34-2.37) 0.84
Meta-analysis (300) 0.46 (0.35-0.61) 1.7131028
rs73208470 Genotypes 4 7323913 G/C 0.143 AA (194) 0.61 (0.44-0.86) 0.0055
0.324 WT (57) 0.34 (0.24-0.51) 3.0931026
0.119 HIS (53) 0.91 (0.34-2.37) 0.84
Meta-analysis (300) 0.50 (0.39-0.65) 8.0431028
AA, African American; b, linear regression coefficient for the ATV concentration in nanograms of ATV per milligram of hair; Chr, chromosome; CI, confidence interval; HIS,
hispanic; WT, white.
aPosition is based on GRCh37/hg19 assembly. Minor/major alleles (A1/A2).
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ATV concentrations in hair are strongly associated with viral sup-
pression.23 As such, we believe the underlying model, that hair
levels are a stable measurement depending primarily on long-
term average serum levels, is a reasonable one. This study provides
evidence that common variants within the SORCS2 gene are
associated with decreased ATV concentration measured in hair.
The Sortilin-related VPS10 domain containing receptor 2
(SORCS2) is a transmembrane glycoprotein receptor and a mem-
ber of vacuolar protein sorting 10 family proteins (VPS10Ps)
that play roles in protein trafﬁcking and intracellular and inter-
cellular signaling.25 It has been implicated in amyotrophic lateral
sclerosis (ALS) 26 and bipolar disease.27,28 More interestingly, in
line with our ﬁndings, previous work reported that three variants
in this gene mediated CYP3A4 induction by St. John’s Wort, but
they found no evidence for NR1I2 association with CYP3A4
overexpression.29 Given that ATV is primarily metabolized
through CYP3A4/3A5 enzymes,30 our ﬁnding of SORCS2
reducing ATV hair concentration would be consistent with over-
expression of the CYP3A4 enzyme. However, the functional
properties of the SORCS2 gene, its protein product, and their
eventual connection to CYP3A4/3A5 or ATV metabolism war-
rants further investigation.
Additionally, within the same region of our ﬁnding (i.e., the
intron 1 of SORCS2) there lies the microRNA MIR4798
(Figure 3). In general, these short noncoding RNAs are involved
in posttranscriptional regulation of gene expression that normally
results in silencing mRNA expression. Although the functional
properties of MIR4798 within the context of ATV expression or
otherwise are unknown, the NR1I2 mRNA is one of the predicted
targets of this particular miRNA (http://www.targetscan.org/
cgi-bin/targetscan/vert_71/targetscan.cgi?mirg=hsa-miR-4798-3p).
This ﬁnding is intriguing because the encoded protein from
NR1I2 (a.k.a. PXR) is a transcriptional regulator of CYP3A431,32
and ABCB1,32 which are involved in metabolism of ATV.
While there are no directly comparable quantitative values
reported in ATV pharmacogenetic literature, we can use plasma
reporting as examples for such comparison, recognizing that
plasma concentrations may not be directly and reliably related to
hair levels. For example, carrying either one or two copies of the
rs1045642 (C3435T) minor allele “T” (“CT” or “TT” geno-
types), a coding SNP of ABCB1, was associated with decreased
ATV minimum concentration in plasma (“CT”/“TT” genotypes:
376 ng/mL (interquartile range (IQR), 221–722) vs. “CC” geno-
type: 939 ng/mL (IQR, 492–1,266), P5 0.001).17 In our study,
presence of the “T” allele had a modest and statistically nonsignif-
icant (P5 0.51) association with increased ATV hair level.
While the conﬁdence interval was too wide to rule out the possi-
bility of substantial effect (fold difference: 1.09, 95% CI: 0.85–
1.41) in hair, it does provide evidence against an effect as large as
0.40-fold observed in plasma.
Remarkably, genetic variants previously reported in ATV phar-
macogenetic studies, such as those in ABCB1,15–18 NR1I2,19,20
and CYP3A4/A5,21,22 were not substantially and statistically sig-
niﬁcantly associated with ATV level in hair, but conﬁdence inter-
vals for some were too wide to rule out the possibility of a
substantial effect. Possible explanations may relate largely to dif-
ferences in what was measured (i.e., oral clearance,21 minimum
plasma concentration)22 and study compartments (i.e., hair vs.
plasma), as well as clinical and demographic differences. Another
explanation could be due to unaccounted factors other than
long-term ATV exposure that could impact ATV hair level. Our
measured phenotypic and environmental covariates, while broad,
may not completely control for variation in long-term ATV
exposure in hair. Notably, actual adherence may have varied
despite uniformly high self-reported adherence.
There are potential limitations to the study that need to be
considered. First, the observed association should be treated as
preliminary until they can be replicated in additional indepen-
dent studies, as is common practice for all GWAS results. While
the effect size in the replication sample is in the same direction as
discovery analysis and interestingly similar to the HIS group used
in the stratiﬁed discovery stage (Figure 4), the replication is not
formally statistically signiﬁcant (P5 0.31), and therefore incon-
clusive. In addition to the obvious precision limitation of the rep-
lication sample, the ethnic heterogeneity may also be a further
limiting factor behind this result. Second, our ﬁndings were
obtained from a relatively small initial sample, a situation which
has in the past produced spurious results.33 Finally, the consider-
able diversity in ethnic origin and the corresponding differences
in allele frequencies and LD patterns across multiethnic samples
could present a challenge with having sufﬁcient power to detect
some variants and overlook true genetic associations.
Figure 4 Forest plot of rs7320847 SNP in SORCS2 for association with
ATV hair level. Each point represents the estimated effect size for the
rs7320847, A allele, transformed to the linear scale (using the function
exp(linear regression beta) for its calculation) for each stratum of the anal-
ysis (AA, African American; WT, White; HIS, Hispanic). “Meta-GWAS” refers
to the meta-analysis of the discovery cohorts, whereas “Replication”
refers to the 79 multiethnic subjects analyzed separately. The bars indi-
cate 95% confidence intervals.
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In summary, this work represents the ﬁrst genome-wide study
to elucidate genetic bases of ATV level in hair. Our ﬁndings sug-
gest a complex combination between genetic and nongenetic fac-
tors. We have also identiﬁed a new candidate gene associated
with ATV hair levels with a reasonable mechanistic basis. The
results also suggest that speciﬁc genetic polymorphisms associated
with ATV exposure may differ when assessed in hair among phe-
notypically and behaviorally complex HIV-positive women (e.g.,
those with HCV infection, concurrent alcohol consumption,
smoking, and users of illicit and other prescribed medication)
under conditions of actual use compared to those in plasma. Our
ﬁndings in hair should not be interpreted as a refutation of exist-
ing literature on ATV pharmacogenetics conducted in plasma,
because of the differences in patient population characteristics
and other differences in effect sizes of risk factors that may need
larger sample sizes for replication. To truly translate genetics into
a change in clinical practice, our ﬁndings support the importance
of conducting pharmacogenetic studies under conditions that
best represent the actual use of a therapy and that consider the
underlying ethnic background of the population, which repre-
sents not only genetic differences but unmeasured cultural
factors.
METHODS
Study population
The WIHS is a multicenter observational cohort study of women with
and at risk for HIV infection with follow-up visits every 6 months.
Informed consent was provided by all participants via protocols
approved by Institutional Review Committees at each afﬁliated institu-
tion. Consent to studies of host genetics was speciﬁcally obtained for
women who contributed to this study. Detailed methods have been pub-
lished previously.34,35 WIHS participants are representative of women
with HIV infection in the US, a group that is not well represented in
antiretroviral drug clinical trials.36 Over a period of 5 years (2003–
2008), 466 WIHS participants reported at least 6 weeks of taking an
ATV containing cART regimen and provided 1,575 hair samples for
measurement of ATV concentration. For individuals with more than
one measurement, the visit with highest level in hair was selected for this
analysis. A subset of 398 individuals had available covariate and GWAS
data for this analysis (Table 1). The only exclusion criteria for this study
were not receiving ATV for at least 6 weeks, incomplete covariate and
genotyping data.
Concentration of ATV in hair
The method for extraction and analysis of ATV in hair using high-
performance liquid chromatography tandem mass spectrometry (HPLC-
MS) has been described previously.23
Genetic and statistical analyses
This study is a linear regression-based GWAS of ATV hair concentra-
tion. Given the need to control for potential bias arising from popula-
tion structure due to WIHS participants’ ethnic diversity, a stratiﬁed
GWAS was conducted in two stages. In the ﬁrst stage, association analy-
ses were performed in each strata of samples representing the most
numerically large homogeneous ethnic groups, using within-group cor-
rection for the main Principal Components, as suggested elsewhere.37 In
the second phase, results from separate strata were combined. Validation
was sought through analyzing samples that were not included in the ﬁrst
step (i.e., WIHS participants who could not be assigned to an ethnic
group stratum), after PC-based adjustment for genetic admixture.
Outcome
The main outcome was ATV level in hair, evaluated as a biomarker of
ATV exposure, which provides a direct measure of long-term ATV expo-
sure. To control for nongenetic factors that can cause signiﬁcant variabil-
ity in blood ATV, and thus hair, over multiple visits for the same
patients, we selected as primary outcome of our analyses the highest
ATV concentration in hair (in ng/mg) for a given participant. The ratio-
nale for this choice is that the genetic effects remain constant over time,
while the confounding from variable factors (e.g., renal function, self-
reported adherence, hepatic function) was at their minimum of their
ﬂuctuating inﬂuence.
Levels in hair below the limit of detection (i.e., <0.05 ng/mg of hair)
were assigned a value of 0.05 ng/mL. Of 1,593 hair samples, 58 had con-
centrations below limit of quantiﬁcation (BLOQ), but only eight partici-
pants in the ﬁnal analysis had ATZ concentrations that were BLOQ.
The empirical distribution of the ATV concentration in hair is not nor-
mally distributed. Thus, for the purpose of statistical analyses, this out-
come was normalized employing transformation (i.e., natural logarithm)
prior to inclusion in regression models.
Independent variables
For the GWAS, the main predictor was the number of the rarer
allele carried at each locus, ranging from 0 to 2. In addition to gen-
otypes, we assessed a variety of nongenetic factors (Table 1) that
may exert nonspeciﬁc inﬂuences over ATV pharmacology, including
age, body mass index (BMI), alcohol use, pregnancy status, self-
reported race/ethnicity, self-reported adherence to cART, self-
reported use of other medications, self-reported use of cocaine,
heroin, or other injectable drugs, and current smoking. To better
control for variation of ATV levels in hair associated with nonge-
netic factors, we additionally assessed clinical laboratory measures
including estimated glomerular ﬁltration rate (EGFR, calculated using
the CKD-EPI equation38, estimated creatinine clearance (calculated
using the Cockcroft–Gault equation) serum aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), gamma-glutamyl transfer-
ase (GGT), total bilirubin, laboratory evidence of chronic hepatitis B
and/or C. Concurrently used medications were assessed for known
impact on ATV pharmacokinetics (e.g., ritonavir, tenofovir, antacids)
(Table S1) and drugs that had these effects were included as covari-
ates in GWAS analysis. The strongest among these factors, which
could increase error in the genetic analyses, were identiﬁed and then
included as GWAS covariates. In brief, nongenetic predictors were
selected following a stepwise backward regression that retained only
variables showing a nominally statistically signiﬁcant association
(P< 0.05) in the ﬁnal multivariable model. As a result, the following
nongenetic predictors were included as covariates in the GWAS: age,
creatinine clearance category (as an ordinal variable), GGT, EGFR,
cocaine use, body height, and concurrent ritonavir use (Table S2).
Genotyping and imputation
Genomic DNA isolated from blood was genotyped on the Illumina
Omni2.5 Array (San Diego, CA) platform (n 2.5 million SNPs).
Rigorous individual level and SNP level quality control were
applied.39 Participants were excluded if they exhibited array-wide call
rates <95%, excess heterozygosity, or relatedness to other WIHS par-
ticipants. Phase information from the 1000 Genomes Project
(Phase 3 v. 5) panel was used to impute these genotypic data
(n 14 million SNPs). Among others, phasing was performed using
the ShapeIT software40 and imputation using minimac3.41 Only indi-
viduals with more than 90% of the genotypes available were included
and hard calls from only SNPs with sufﬁcient imputation quality
scores (RSQ >0.5) and with minor allele frequencies (MAF) >0.05
and Hardy–Weinberg equilibrium (HWE) P> 0.001 within each
ethnic group were used for the analyses (n 11.4 million SNPs). In
total, 14 million SNPs were available for analysis.
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Linear regression
In the stratiﬁed analysis, only ethnic groups comprised of more than 50
subjects among our genotyped samples were considered as a stratum,
which were analyzed separately for association with ATV exposure in
hair using PLINK 1.9 (https://www.cog-genomics.org/plink2). This
threshold of inclusion (n5 50) corresponds to a minimum of ﬁve het-
erozygous participants for the lowest MAF analyzed (MAF5 0.05). To
further control for potential residual population structure within these
ethnically homogeneous strata, we adjusted for the ﬁrst three principal
components37 (Figure S1) as well as seven clinical and demographic
covariates selected as described above.
Results from each stratum were combined using GWAMA,42 using a
ﬁxed-effect inverse-variance model on results adjusted for the genomic
control inﬂation factor (GC, or k) 43 observed in each stratum. In addi-
tion to prior within-ethnic group inclusion thresholds, only results
observed from sufﬁciently large samples (deﬁned as >240 participants,
or 80% of the original sample) were considered further. Cochran’s Q
test and I2 were used to assess heterogeneity across strata and results with
large effect heterogeneity (deﬁned as I2 >75%) were removed from fur-
ther consideration. For the GWAS, the conventional signiﬁcance thresh-
old of 5 3 1028 was adopted.44 Results were annotated to the nearest
gene using SNPnexus.45–47
PharmGKB database lookup
The pharmacogenomics knowledgebase (pharmGKB) database48 is a
curated database of pharmacogenomically important variants and their
impact on any known drug response. The reference sequence identiﬁers
(rsID) (https://www.pharmgkb.org/downloads/; Accession date: May
2017) of 5,098 variants in this database were downloaded and used as an
unbiased source to annotate and evaluate for pharmacogene variant asso-
ciations with ATV hair concentrations in this study. Additionally var-
iants in ABCB1,15–17 NR1I2,19,20 CYP3A5,21,22 which are reported in
pharmacogenetic studies of ATV in plasma were assessed for association
with ATV concentration measured in hair. Of the 5,098 variants present
in the pharmGKB at the time of the query, 3,877 were sufﬁciently com-
mon and passed quality controls to be assessed in the current study. For
evaluation of associations among these loci, a Bonferroni adjusted signiﬁ-
cance threshold of 0.05/3,8775 1.29310205 was considered, while not-
ing that SNPs are not always independent and this threshold may be too
conservative.
Additional Supporting Information may be found in the online version of
this article.
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